此外，通过检测 RAD51 焦点发现，Chk1 和 Wee1 抑制会降低同源重组（Homologous Recombination，HR）效率，导致 DSB 持续存在。 Chk1 和 Wee1 抑制使 HNSCC 细胞对低 LET 和高 LET 的 PBT 均更敏感：研究人员进一步探究了抑制 Chk1 或 Wee1 激酶联合 PBT 的效果。结果显示，无论是低 ...

为解决多发性骨髓瘤（MM）预后评估指标局限问题，研究人员开展 WEE1 基因相关研究。结果发现 WEE1 表达可独立预测 MM 预后，且与 P53 通路有关。该研究为 MM 预后判断和治疗提供新方向，值得科研读者一读。 多发性骨髓瘤（Multiple Myeloma，MM）是一种血液系统恶性 ...

Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the ...

Improved safety window compared to single-target WEE1 inhibitors The Phase I clinical trial, set to launch in 2025, will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti ...

Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects Superior efficacy as a single agent and in combination therapies across various cancer models Preferential ...